Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Platinum-based regimens have been the most commonly used salvage therapy for non-Hodgkin's lymphoma (NHL). In this update of two of these regimens with long-term follow-up data, we provide evidence that the etoposide-containing regimen (ESHAP) is superior to a cisplatin-cytosine arabinoside-based regimen (DHAP) in response rate, survival, and time to treatment failure. In spite of this superiority, the long-term outcome for most patients with relapsed or refractory NHL remains unfavorable. Newer salvage regimens such as MINE-ESHAP, or, when feasible, high-dose chemotherapy with transplant, are probably better choices than either DHAP or ESHAP alone.
Rodriguez-Monge
E J
EJ
Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Cabanillas
F
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D015993:Life Tables; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D015080:Mesna / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D011379:Prognosis; D016879:Salvage Therapy; D013781:Texas / Q000453:epidemiology; D016896:Treatment Outcome
D003561:Cytarabine; D008776:Methylprednisolone Hemisuccinate; D005047:Etoposide; D003907:Dexamethasone; D008942:Mitoxantrone; D015080:Mesna; D002945:Cisplatin; D007069:Ifosfamide; D008775:Methylprednisolone